BioStock publishes article after Prolight signed supply agreement with BRAINBox valued at USD 3.9 million

About Us
Prolight Diagnostics develops Psyros^®, a groundbreaking Point-of-Care platform for highly sensitive biomarker diagnostics. By delivering reliable test results in ten minutes or less, Psyros has the potential to revolutionize clinical workflows, improve patient outcomes, and reduce healthcare costs. The platform is initially being developed for areas with significant unmet medical needs such as cardiovascular and neurological conditions and possesses broad potential for a wide range of clinical applications.
 
The company’s share is traded on the NGM Growth Market marketplace, under the ticker PRLD.